Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 2010 results found since Jan 2013.

Interventions to improve vaccine acceptance among rheumatoid arthritis patients: a systematic review
ConclusionsInterventions to enhance vaccine uptake in RA focused almost exclusively on improving provider prescription of vaccines using reminder-type interventions. Although effective in improving vaccination rates, those studies used heterogeneous interventions and behavior change techniques. Few studies measured provider prescribing behavior as an outcome. Future studies targeting providers should measure relevant provided-related outcomes and their impact on patient outcomes, to determine overall efficacy.
Source: Clinical Rheumatology - January 15, 2019 Category: Rheumatology Source Type: research

Update in Herpes Zoster Prevention and the Role of Dermatologists
Authors: Feli KH, Ediale CE, McMichael AJ Abstract A recombinant vaccine (HZ/su) was approved in 2017 to prevent herpes zoster (HZ) infection and associated sequelae with greater efficacy and safety than its live precursor. Though dermatologists regularly encounter patients with HZ infection, recommendation of vaccination by dermatologists and other physicians has been minimal in past years. Overall patient awareness and utilization of the HZ vaccines has subsequently been low. While HZ/su touts several improvements over the live vaccine, dermatologists still face obstacles to vaccine recommendation and administrat...
Source: Journal of Drugs in Dermatology - January 27, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Composition and mode of action of adjuvants in licensed viral vaccines.
In this report, adjuvants that are components of vaccines licensed in the EU will be presented and their mode of action will be discussed.Aluminum salts have been used for almost a century as vaccine adjuvants. In recent years numerous novel immune-stimulating substances have been developed and integrated into licensed human vaccines. These novel adjuvants are not only intended to generally increase the vaccine-induced antibody titers, but are also aimed at modulating and triggering a specific immune response. The search for innovative adjuvants was considerably stimulated during development of pandemic influenza vaccine...
Source: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz - March 3, 2019 Category: International Medicine & Public Health Authors: Wagner R, Hildt E Tags: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Source Type: research

Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
Authors: Wu KK, Lee MP, Lee EB, Wu JJ Abstract Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. However, adverse events related to the immunosuppressive properties of these biologics have been observed. This review aims to synthesize and evaluate the literature investigating the risk of HZ in patients treated with IL-17 inhibitors, with a focus on psoriasis patients. Clinical trials, cohort st...
Source: Journal of Dermatological Treatment - March 24, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review
ConclusionThe most advanced phase III clinical applications led to the development of two vaccines containing QS-21 as part of AS, the Herpes Zoster vaccine (HZ/su) (ShingrixTM) which received a license in 2017 from the FDA and a marketing authorization in EU in 2018 and the RTS,S/AS01 vaccine (MosquirixTM) against malaria which was approved by the EMA in 2015 for further implementation in Sub Saharan countries for routine use.Graphical abstract
Source: Phytomedicine - April 1, 2019 Category: Drugs & Pharmacology Source Type: research

Vaccines for preventing herpes zoster in older adults.
CONCLUSIONS: LZV and RZV are effective in preventing herpes zoster disease for up to three years (the main studies did not follow participants for more than three years). To date, there are no data to recommend revaccination after receiving the basic schedule for each type of vaccine. Both vaccines produce systemic and injection site adverse events of mild to moderate intensity. PMID: 31696946 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 6, 2019 Category: General Medicine Authors: Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, Canteiro Cruz E Tags: Cochrane Database Syst Rev Source Type: research

Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment
Expert Rev Anti Infect Ther. 2021 Apr 14. doi: 10.1080/14787210.2021.1917992. Online ahead of print.ABSTRACTINTRODUCTION: Acyclovir has led to the development of successful systemic therapy for herpes simplex virus and varicella-zoster virus (VZV) infection, and the use of valacyclovir and famciclovir has improved treatment. Additionally, the use of a helicase-primase (HP) inhibitor (HPI), amenamevir, is changing the treatment of herpes zoster (HZ).AREA COVERED: VZV infection is prevented by vaccines and is treated with antiviral agents. Acyclovir and penciclovir are phosphorylated by viral thymidine kinase and work as cha...
Source: Expert Review of Anti-Infective Therapy - April 15, 2021 Category: Infectious Diseases Authors: Kimiyasu Shiraki Masaya Takemoto Tohru Daikoku Source Type: research